Figure 3 | British Journal of Cancer

Figure 3

From: Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR

Figure 3

The biodistribution over 7 days of 111In-CHX-A″-DTPA- and 125I-labelled ch806 in (A) U87MG.de2-7 xenografts, (B) A431 xenografts, (C) FaDu xenografts and serum from BALB/c nude mice. Results are expressed as mean (bars; ±s.d.) percent injected dose per gram (%ID g−1) for each time point, (n=3–5 mice). The data are presented as: 111In-serum (▪); 111In-tumour (▴), 125I-serum (•), and 125I-tumour (▾).

Back to article page